Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(3)
•••
Comment by themagicboxon Jul 06, 2020 10:01am
213 Views
Post# 31228039

RE:RE:RE:RE:Be Careful

RE:RE:RE:RE:Be CarefulYou're whats wrong haha. Your argument would make more sense if ATE did not meet its ph2 primary endpoints. ATE crushed it in results.

Both the 250 mg and 200 mg demonstrated unequivocal superiority to placebo, with a high level of statistical significance.  Bellus didn't reach statistical significance.

The 150 mg was more potent than expected: dose showed a strong efficacy response — lowest effective dose still to be established. Thats how good ATE was. 

C*mster, are you really trying to help and warn everyone? You care that much about other peoples money and investments? Why dont you help others out and tell what other investments you have going on? lol

Duster340 wrote: are you kidding me what is wrong with you people, i am just saying anyone that is invested in other drug companies going into phase 2. be careful things don't always go the way you think, look at what happened to bellus health 75% of it's value gone overnight.i bought a 1/3 possition of ate last week 


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities